ATM and B-cell chronic lymphocytic leukemia: In separate studies from the UK Leukemia Research Fund CLL 4 trial, patients with ATM mutations treated with chemotherapy exhibited shorter progression-free survival (PFS) and overall survival (OS) compared to ATM-wildtype patients, though the differences did not reach statistical significance [7, 17].